SKC podcast

#09 Research is the best medicine

Tue, 2023 / 01 / 31
Han Steutel is president of the German association of research-based pharmaceutical companies (Verband Forschender Arzneimittelhersteller e.V., vfa), representing more than two-thirds of the entire German pharmaceutical market.

In our podcast series "The Profcast - rare diseases and their therapies" he talks with Prof. Matthias P. Schönermark about the effects of the German Act to Stabilize the Finances of Statutory Health Insurance (GKV-FinStG) on orphan drugs and German pharmaceutical research, as well as the positive successes and prospects of gene therapies and other ATMPs (advanced therapeutic medicinal products).

You can find Profcast #09 Research is the best medicine on Spotify und Apple Podcast (in German language only). Listen now!

About the Profcast

Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.

The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.


About the author

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

Orphan drugs in Deutschland

Medikamente für seltene Erkrankungen, sog. orphan drugs, und ihre spezifischen Herausforderungen beim Market Access zählen zu unseren Kernkompetenzen.
to the top